Yes
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Equivocal Evidence |
GLIOMA 0/50 2/48 1/49
|
May Have Been Related
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
PAPILLOMA 0/49 4/42 10/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
PAPILLOMA 0/49 5/40 0/44
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 1/50 10/49 10/49
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 0/50 23/50 29/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/47 4/49 OR CARCINOMA 0/50 1/47 1/49 COMBINED 0/50 2/47 5/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 9/48 20/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 6/48 8/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 12/49 11/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 2/49 5/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ACINAR CELL CARCINOMA 0/50 2/49 6/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
GRANULOSA CELL TUMOR 0/49 6/45 12/48
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 0/50 3/50 1/50
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Equivocal Evidence |
NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80
|
May Have Been Related
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 11/48 18/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 16/49 7/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
(STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50
|
May Have Been Related
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/50 2/50
|
May Have Been Related
|
Yes
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/60 2/44 3/75 1/60
|
May Have Been Related
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/60 2/45 14/75 20/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 2/60 1/45 7/75 6/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60
|
Neoplastic Lesions
|
No
|
TR-372
|
20325-40-0 |
3,3'-Dimethoxybenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60
|
Neoplastic Lesions
|
Yes
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60
|
May Have Been Related
|
Yes
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60
|
May Have Been Related
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60
|
May Have Been Related
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 2/45 7/75 4/60 OR ADENOCARCINOMA 0/60 0/45 3/75 6/60 COMBINED 0/60 2/45 10/75 9/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/60 0/45 7/75 10/60 OR ADENOCARCINOMA 0/60 0/45 3/75 15/60 COMBINED 0/60 0/45 10/75 23/75
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 0/45 7/74 3/60 OR CARCINOMA 0/60 0/45 1/74 1/60 COMBINED 0/60 0/45 7/74 4/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/60 0/45 29/75 26/60 OR CARCINOMA 0/60 0/45 12/75 12/60 COMBINED 0/60 0/45 35/75 33/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 1/45 3/74 3/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 0/74 1/60 COMBINED 1/60 1/45 3/74 4/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 0/45 7/75 6/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 1/75 0/60 COMBINED 1/60 0/45 8/75 6/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/60 1/45 3/75 6/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/60 0/45 3/75 4/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/60 3/45 7/75 9/60 OR SQUAMOUS CELL CARCINOMA 0/60 1/45 2/75 4/60 COMBINED 0/60 3/45 9/75 13/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 2/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 1/75 3/60 COMBINED 0/60 0/45 4/75 5/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/60 4/45 4/75 8/60 OR CARCINOMA 0/60 0/45 2/75 1/60 COMBINED 2/60 4/45 6/75 9/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/60 4/45 11/75 12/60 OR CARCINOMA 0/60 2/45 22/75 35/60 COMBINED 0/57 6/45 32/75 42/60
|
Neoplastic Lesions
|
No
|
TR-390
|
612-82-8 |
3,3'-Dimethylbenzidine dihydrochloride |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/60 1/45 13/75 16/60 OR CARCINOMA 0/60 2/45 21/75 23/60 COMBINED 1/60 3/45 32/75 36/60
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Male |
Inhalation |
Adrenal Gland Medulla
|
Some Evidence |
Some Evidence |
PHEOCHROMOCYTOMA 8/48 23/47 17/50 21/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 2/50 0/49 COMBINED 8/48 23/47 18/50 21/49
|
Neoplastic Lesions
|
Yes
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Male |
Inhalation |
Brain
|
Some Evidence |
Equivocal Evidence |
GRANULAR CELL TUMOR 0/49 3/50 1/50 1/50; GLIOMA 0/49 1/50 0/50 0/50, ASTROCYTOMA 0/49 1/50 0/50 0/50, OR OLIGODENDROGLIOMA 0/49 1/50 0/50 0/50 COMBINED 0/49 3/50 0/50 0/50
|
May Have Been Related
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Female |
Inhalation |
Brain
|
Equivocal Evidence |
Equivocal Evidence |
GLIOMA 0/50 1/50 1/48 3/50
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Some Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/48 0/49 1/48 1/48 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/48 0/49 3/48 0/48 COMBINED 0/48 0/49 4/48 1/48
|
May Have Been Related
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 6/50 8/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 0/50 5/50 6/50 COMBINED 7/50 6/50 12/50 15/50
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/48 0/47 3/49
|
Neoplastic Lesions
|
No
|
TR-363
|
74-96-4 |
Bromoethane (ethyl bromide) |
Mice |
B6C3F1 |
Female |
Inhalation |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 1/47 6/48, ADENOCARCINOMA 0/50 2/50 3/47 19/48, OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/47 3/48 COMBINED 0/50 4/50 5/47 27/48
|
Neoplastic Lesions
|
Yes
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/50 1/35 1/65 2/50
|
May Have Been Related
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Equivocal Evidence |
MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50
|
May Have Been Related
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/35 3/65 1/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 6/65 8/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 0/35 1/65 3/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
NEOPLASMS 0/50 1/35 0/65 2/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Female |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50
|
Neoplastic Lesions
|
No
|
TR-397
|
2429-74-5 |
C.I. Direct Blue 15 |
Rats |
F344/N |
Male |
Dosed-Water |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Adrenal Gland Medulla
|
Equivocal Evidence |
Equivocal Evidence |
benign, malignant, or complex pheochromocytoma (1/86, 9/89, 5/87, 4/88)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Brain
|
Equivocal Evidence |
Equivocal Evidence |
glioma malignant (0/90, 3/90, 0/90, 0/90)
|
May Have Been Related
|
Yes
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Brain
|
Clear Evidence |
Clear Evidence |
glioma malignant (0/90, 0/90, 0/90, 3/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Heart
|
Equivocal Evidence |
Equivocal Evidence |
schwannoma malignant (0/90, 2/90, 0/90, 2/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Heart
|
Clear Evidence |
Clear Evidence |
schwannoma malignant (0/90, 2/90, 3/90, 6/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Liver
|
Clear Evidence |
Equivocal Evidence |
hepatocellular adenoma or carcinoma (combined) (0/90, 2/90, 4/89, 1/88)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADCDMA |
Cell Phone Radiation: CDMA |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Pituitary Gland
|
Clear Evidence |
Equivocal Evidence |
pars distalis, adenoma (17/89, 25/90, 34/90, 13/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Adrenal Gland Medulla
|
Clear Evidence |
Clear Evidence |
benign, malignant, or complex pheochromocytoma (11/88, 24/90, 28/89, 14/87)
|
Neoplastic Lesions
|
Yes
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Brain
|
Clear Evidence |
Equivocal Evidence |
meninges, granular cell tumor benign or malignant (1/90, 3/90, 4/90, 3/90)
|
May Have Been Related
|
Yes
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Brain
|
Clear Evidence |
Clear Evidence |
glioma malignant (0/90, 3/90, 3/90, 2/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Female |
Whole Body Exposure |
Heart
|
Equivocal Evidence |
Equivocal Evidence |
schwannoma malignant (0/90, 0/90, 2/90, 0/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Heart
|
Clear Evidence |
Clear Evidence |
schwannoma malignant (0/90, 2/90, 1/90, 5/90)
|
Neoplastic Lesions
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Pancreas Islet Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma (13/90, 27/89, 19/86, 16/85)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Pituitary Gland
|
Clear Evidence |
Equivocal Evidence |
pars distalis, adenoma (17/89, 28/90, 26/90, 26/90)
|
May Have Been Related
|
No
|
TR-595
|
CELLPRADGSM |
Cell Phone Radiation: GSM |
Rats |
Hsd:Sprague Dawley SD |
Male |
Whole Body Exposure |
Prostate Gland
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma (2/90, 2/90, 7/90, 3/90)
|
May Have Been Related
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 4/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Epididymis
|
Clear Evidence |
Equivocal Evidence |
SARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Equivocal Evidence |
FIBROSARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 13/50 14/50 20/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 3/50 8/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 3/50 34/50 39/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 3/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Female |
Inhalation |
Brain
|
Some Evidence |
Equivocal Evidence |
ASTROCYTOMA 0/50 0/50 1/50 0/50, GLIOMA 0/50 0/50 0/50 1/50, MEDULOBLASTOMA 0/50 0/50 0/50 1/50, MENINGEAL GRANULAR CELL TUMOR 0/50 1/50 0/50 1/50, MENINGEAL SARCOMA 0/50 1/50 0/50 1/50
|
May Have Been Related
|
No
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTION) ADENOMA 0/50 2/50 2/50 6/50 (SINGLE AND STEP SECTION) ADENOMA 2/50 4/50 8/50 15/50
|
Neoplastic Lesions
|
No
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Male |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 2/50 4/50 6/50 21/50 FIBROADENOMA OR CARCINOMA COMBINED 2/50 5/50 7/50 21/50
|
Neoplastic Lesions
|
No
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Some Evidence |
Some Evidence |
FIBROADENOMA 19/50 35/50 32/50 32/50 MULTIPLE FIBROADENOMA 7/50 12/50 19/50 17/50
|
Neoplastic Lesions
|
No
|
TR-486
|
78-79-5 |
Isoprene |
Rats |
F344/N |
Male |
Inhalation |
Testis
|
Clear Evidence |
Clear Evidence |
ADENOMA 33/50 37/50 44/50 48/50
|
Neoplastic Lesions
|
Yes
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
Yes
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
Yes
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(NEUROBLASTOMA)
|
Neoplastic Lesions
|
Yes
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Brain
|
Positive |
Positive |
(ADENOCARCINOMA, NEUROBLASTOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Male |
Intraperitoneal Injection |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Female |
Intraperitoneal Injection |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Rats |
Sprague Dawley |
Male |
Intraperitoneal Injection |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-019
|
366-70-1 |
Procarbazine hydrochloride |
Mice |
B6C3F1 |
Female |
Intraperitoneal Injection |
Uterus/Cervix
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
All Organs
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 1/50 12/50 18/50 37/50
|
Neoplastic Lesions
|
Yes
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Female |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 3/50 1/50
|
May Have Been Related
|
Yes
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
Brain
|
Clear Evidence |
Equivocal Evidence |
glioma or oligodendroglioma (original and extended evaluations combined): 0/50 1/50 4/50 3/50
|
May Have Been Related
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 6/50 11/50 14/49 19/51 adenoma or carcinoma 6/50 11/50 14/49 20/51
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 33/49 42/50 42/49 44/50 hepatocellular carcinoma 9/49 17/50 22/49 26/50 hepatoblastoma 0/49 1/50 4/49 6/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 36/49 44/50 43/49 46/50
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 12/50 22/50 27/49 39/51 hepatoblastoma 4/50 24/50 40/49 34/51
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
fibroadenoma 28/50 47/50 47/50 39/50 carcinoma 0/50 1/50 3/50 8/50 fibroadenoma, adenoma, or carcinoma 28/50 47/50 48/50 42/50
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
(oral mucosa and tongue): squamous cell papilloma or squamous cell carcinoma 1/50 0/50 3/50 3/50
|
May Have Been Related
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(subcutaneous tissue): fibroma 4/50 6/50 10/50 15/50
|
Neoplastic Lesions
|
No
|
TR-583
|
71133-14-7 |
Water disinfection byproducts (Bromodichloroacetic Acid) |
Rats |
F344/NTac |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma, keratoacanthoma, sebaceous gland adenoma, basal cell adenoma, basal cell carcinoma, or squamous cell carcinoma 9/50 7/50 15/50 21/50
|
Neoplastic Lesions
|